ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers

The ICR responds to the announcement by NICE that the immunotherapy nivolumab (Opdivo) will now be made available on the Cancer Drugs Fund for non-small cell lung cancers.
Institute of Cancer Research